Latest Pharma and Biotech News
Biotechnology
11 December 2025 Chinese regulator the National Medical Products Administration (NMPA) has approved two innovative medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura, both from French pharma major Sanofi.
Today's issue
Refine Search
Pharmaceutical
British pharma major AstraZeneca has joined a near-$100 million series A and A+ financing round for Syneron Bio, a biotechnology startup focused on macrocyclic peptide therapies for oncology and chronic diseases. 12 December 2025
Pharmaceutical
Danish biotech Sidera Bio has raised about 700 million kroner ($109 million) in a series A financing, one of the largest early-stage biotech rounds ever completed in Denmark. Investors include Novo Holdings, Forbion, RA Capital Healthcare Fund and Gilde Healthcare. 12 December 2025
Pharmaceutical
New York, USA-based rare disease firm Applied Therapeutics has announced a definitive agreement to be acquired by privately-held UK-based Cycle Pharmaceuticals. 12 December 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for the use of an oral pellet formulation of once-daily Orladeyo (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to <12 years. 12 December 2025
Biotechnology
US late-stage rare disease focused pharma Rezolute announced disappointing top-line results from its Phase III sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI) with news sending its shares crashing 87% to $1.40 by close of trading yesterday. 12 December 2025
Pharmaceutical
Medra, a US company developing the first platform for physical AI scientists, has announced a $52 million Series A financing. 12 December 2025
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of plexiform neurofibromas in adults and adolescents. 12 December 2025
Pharmaceutical
Eli Lilly has shown the strength of its obesity pipeline beyond its on-market blockbuster Mounjaro (tirzepatide) 12 December 2025
Biotechnology
California, USA-based biotech Prolynx, which is developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, has announced the closing of a $70 million Series A financing and the appointment of industry veteran Chris Boulton as chief executive (CEO). 12 December 2025
Generics
Irish pharma manufacturer Gaelic Laboratories has acquired Athlone Laboratories, another Irish producer focused on oral dose beta-lactam antibiotics. The transaction brings together two established domestic manufacturers as demand for established antibiotics remains resilient across hospital and outpatient settings. 12 December 2025
Pharmaceutical
The European Medicines Agency has welcomed a political agreement between EU institutions on a far-reaching reform of pharmaceutical legislation, calling it the biggest overhaul of the system in more than two decades. 12 December 2025
Biotechnology
US biotech Amgen has won approval from the US regulator for Uplizna (inebilizumab-cdon) to treat adults with generalized myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive. It is the antibody’s third US approval overall. 12 December 2025
Pharmaceutical
Digital health stakeholders - including developers, policymakers, payers, and providers - are actively shaping and accelerating the adoption of digital health solutions, according to a new report from IQVIA. 12 December 2025
Biotechnology
US pharma major Bristol Myers Squibb has announced progress for its multi-indication cancer drug Opdivo (nivolumab) in another oncology setting. 11 December 2025
Pharmaceutical
Denmark’s Zealand Pharma and Chinese biotech OTR Therapeutics have announced a multi-program strategic collaboration and license deal to discover and develop novel therapeutics for metabolic diseases. 11 December 2025
Pharmaceutical
Switzerland-based Roivant hosted an Investor Day in New York City today, highlighting its leadership with key pipeline updates and provided an update on the company’s strategy for long-term value creation, which saw the firm’s shares rise 6.6% to $21.58 in morning trading. 11 December 2025
Biotechnology
Dutch privately-held company ProteoNic, a provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic technology has been licensed by Ginkgo Bioworks for use in a project awarded to Ginkgo by the Biomedical Advanced Research and Development Authority (BARDA). 11 December 2025
Biotechnology
Swiss clinical-stage biotech AC Immune today announced positive interim safety and efficacy results from the Phase II VacSYn trial of its wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in early Parkinson’s disease (PD), sending its share up more than 40% in pre-market activity, although they dropped as full trading got underway. 11 December 2025
Pharmaceutical
As a physical embodiment of the ambition of Accord Healthcare to establish itself as a leader in the global health landscape, the company’s new office in Stockley Park, London, is as impressive as it gets. 11 December 2025
Pharmaceutical
Swiss pharma giant Roche has announced positive data from the Phase III lidERA Breast Cancer study of giredestrant as an adjuvant endocrine treatment for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, early-stage breast cancer. 11 December 2025
All news
Biotechnology
Amgen has reported stronger-than-expected third-quarter results, driven by double-digit gains across several of its key medicines. Revenue rose 12% year over year to $9.6 billion, ahead of analyst forecasts. 5 November 2025
Biotechnology
California-based Azalea Therapeutics, a biotech promising to redefine precision genomic medicines in vivo, has announced its official launch and completion of $82 million in seed and Series A financing to advance its proprietary enveloped delivery vehicle (EDV) technology. 5 November 2025
Pharmaceutical
Less than six months after ending a short-lived partnership, US telehealth firm Hims & Hers and Danish drugmaker Novo Nordisk are in active discussions over a renewed deal for Wegovy (semaglutide). 5 November 2025
Pharmaceutical
Novo Nordisk today presented new data from the OASIS 4 Phase III trial that explored a variety of patients and hypotheses, adding to the body of evidence supporting this potential treatment option for its GLP-1 drug Wegovy (semaglutide) pill formulation. 5 November 2025
Biotechnology
US biopharma firm Viridian Therapeutics today announced the successful submission of its biologics license application (BLA) to the US Food and Drug Administration (FDA) for veligrotug, the company’s investigational therapy for the treatment of thyroid eye disease (TED). 5 November 2025
Pharmaceutical
Sweden’s Moberg Pharma has entered into an exclusive licensing agreement with Karo Healthcare regarding the commercialization of MOB-015 (Terclara) in Europe. 5 November 2025
Biosimilars
Swiss generics and biosimilars major Sandoz has announced a strategic agreement with Germany’s Evotec to acquire all issued and outstanding equity interests of Just-Evotec Biologics EU SAS (JEB SAS) which includes the Toulouse manufacturing site. 5 November 2025
Pharmaceutical
Danish pharma major Novo Nordisk today announced financial results for the first nine months of 2025, showing that group net sales were 229.92 billion kroner ($35.37 billion), up 12% as reported and +15% at constant exchange rates (CER). 5 November 2025
Biotechnology
China’s National Medical Products Administration (NMPA) in China has recently approved Sichuan Kelun Biotech’s Sutaray (trastuzumab botidotin) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (BC). 5 November 2025
Pharmaceutical
Trade group Pharmaceutical Research and Manufacturers of America (PhRMA) recently submitted comments to inform the Office of the UDS Trade Representative’s (USTR) annual National Trade Estimate (NTE) Report on Foreign Trade Barriers. 5 November 2025
Biotechnology
In a further step in South Korea-based Celltrion’s ambitions to diversify from its core biosimilars focus, the company has entered into an exclusive global licensing agreement with US biotech Kaigene for two of Kaigene's non-clinical-stage assets, KG006 and KG002, targeting autoimmune disorders. 4 November 2025
Pharmaceutical
German pharma major Boehringer Ingelheim has broadened its collaboration with Swiss biotech CDR-Life through a global licensing agreement for CDR111, a trispecific M-gager designed to treat autoimmune diseases. The deal carries a potential value of about $570 million, including $48 million in upfront and near-term payments. 4 November 2025
Pharmaceutical
US pharma giant Pfizer reported financial results for the third quarter of 2025 on Tuesday. 4 November 2025
Biotechnology
Italy based clinical-stage biotech AAVantgarde Bio today announced the successful closing of a $141 million (122 million euros) Series B financing round. 4 November 2025
Pharmaceutical
The bidding war for US obesity focused biotech Metsera, which has attracted offers from Pfizer and Novo Nordisk , and resulted in lawsuits by the US giant taking legal action against the Danish firm and Metsera, has taken a further step. 4 November 2025
Pharmaceutical
US pharma major Eli Lilly has revealed plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. 4 November 2025
Biotechnology
US pharma giant Merck & Co, known as MSD outside of the USA and Canada, today announced that the company, through subsidiary Prometheus BioSciences, has reached an agreement with Germany’s Dr Falk Pharma GmbH to discontinue an existing contract concerning co-development and co-commercialization rights in certain territories for MK-8690 (formerly PRA-052). 4 November 2025
Pharmaceutical
US biopharma Vertex Pharmaceuticals has reported consolidated financial results for the third quarter of 2025 and refined its full year financial guidance. 4 November 2025
Pharmaceutical
UK biotech Slingshot Therapeutics, part of the Syncona Accelerator, has expanded its senior team with the appointments of John Isaac as chief scientific officer and Bobby Soni as chief business officer. The move supports the company’s strategy to advance early-stage academic research into drug candidates ready for clinical development. 4 November 2025
Pharmaceutical
Swiss specialty drugmaker Santhera Pharmaceuticals saw its shares rise 5.8% to 10.90 francs today, after it reported positive top-line results from an analysis of long-term data, including first assessments from the ongoing, open-label, multicenter GUARDIAN study evaluating Agamree (vamorolone) in patients with Duchenne muscular dystrophy (DMD). 4 November 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Ginkgo Bioworks is headquartered in Boston, Massachusetts, where it operates its central “Foundry” for high-throughput cell engineering. The company supports partners globally across biopharma, agriculture, industrial biotechnology, and biosecurity through its Boston-based infrastructure and distributed digital platforms.
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze